Proposal of a New Risk Score for Patients Treated with Transarterial Chemoembolization due to Recurrent Hepatocellular Carcinoma after Curative Resection: A Multicenter Study.
Mi Young JeonBeom Kyung KimJun Yong ParkDo Young KimSang Hoon AhnKwang-Hyub HanJeong-Hoon LeeSu Jong YuYun Joon KimJung Hwan YoonEun-Ju ChoSeung-Up KimPublished in: Gut and liver (2021)
A new pHAP score optimized for patients treated with TACE due to recurrent HCC after resection showed acceptable accuracy and was externally validated. Further studies of means by which to select treatment options other than TACE for high-risk patients according to pHAP scores are warranted.